Right Now May Be the Best Buy-In Window for RedHill Biopharma Ltd. (RDHL) – Invest Chronicle

Right Now May Be the Best Buy-In Window for RedHill Biopharma Ltd. (RDHL)

For the readers interested in the stock health of RedHill Biopharma Ltd. (RDHL). It is currently valued at $2.47. When the transactions were called off in the previous session, Stock hit the highs of $2.52, after setting-off with the price of $2.49. Company’s stock value dipped to $2.34 during the trading on the day. When the trading was stopped its value was $2.44.Recently in News on January 13, 2022, RedHill Biopharma’s Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients. – In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days; Median of 10 days for viral clearance in the opaganib arm vs. clearance median not reached by end of 14-day treatment in placebo arm (Hazard Ratio 1.34; nominal p-value=0.043, N=437/463). You can read further details here

RedHill Biopharma Ltd. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.85 on 01/03/22, with the lowest value was $2.34 for the same time period, recorded on 01/12/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


RedHill Biopharma Ltd. (RDHL) full year performance was -67.68%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, RedHill Biopharma Ltd. shares are logging -78.56% during the 52-week period from high price, and 10.27% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.24 and $11.52.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1260771 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the RedHill Biopharma Ltd. (RDHL) recorded performance in the market was -5.43%, having the revenues showcasing -49.38% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 122.85M, as it employees total of 182 workers.

Market experts do have their say about RedHill Biopharma Ltd. (RDHL)

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.62, with a change in the price was noted -4.57. In a similar fashion, RedHill Biopharma Ltd. posted a movement of -64.51% for the period of last 100 days, recording 1,086,860 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RDHL is recording 7.66 at the time of this writing. In addition, long term Debt to Equity ratio is set at 7.51.

>> 7 Top Picks for the Post-Pandemic Economy << 

Technical breakdown of RedHill Biopharma Ltd. (RDHL)

Raw Stochastic average of RedHill Biopharma Ltd. in the period of last 50 days is set at 7.82%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 45.28%. In the last 20 days, the company’s Stochastic %K was 39.78% and its Stochastic %D was recorded 38.58%.

Bearing in mind the latest performance of RedHill Biopharma Ltd., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -5.43%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -59.13%, alongside a downfall of -67.68% for the period of the last 12 months. The shares increased approximately by -0.41% in the 7-day charts and went up by -14.69% in the period of the last 30 days. Common stock shares were lifted by -49.38% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts